We are live on ! Find out more
LJPC

La Jolla Pharmaceutical Company

Delisted

LJPC was delisted on the 19th of August, 2022.

0 hedge funds and large institutions have $0 invested in La Jolla Pharmaceutical Company in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 41 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 410 (-41)

100% less funds holding in top 10

Funds holding in top 10: 30 (-3)

100% less capital invested

Capital invested by funds: $53.9M → $0 (-$53.9M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 41

Holders
Holders Change
-41
Holders Change %
-100%
% of All Funds
Holding in Top 10
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-100%
% of All Funds
New
Increased
Reduced
Closed
41
Calls
Puts
Net Calls
Net Calls Change

LJPC Hedge Fund Activity: Q3 2022 in Review

0 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in La Jolla Pharmaceutical Company (LJPC) for Q3 2022, worth a combined $0 — down 100% from $53.9M a quarter earlier.

Sellers outnumbered buyers: 41 funds closed out of LJPC and 0 opened new positions — a net loss of 41 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Tang Capital Management, exiting entirely with an estimated $30.6M sold.

  • 0 institutional investors held La Jolla Pharmaceutical Company (LJPC) as of Q3 2022, down from 41 in Q2 2022.
  • Funds reported $0 of La Jolla Pharmaceutical Company stock for Q3 2022, down 100% quarter-over-quarter.
  • 0 funds opened new La Jolla Pharmaceutical Company positions in Q3 2022 and 41 closed out, a net change of -41 holders.
  • The largest La Jolla Pharmaceutical Company seller in Q3 2022 was Tang Capital Management, an estimated $30.6M sold.

Based on aggregated 13F filings for Q3 2022.